Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-06 00:30 | 2026-01-02 | XLO | Xilio Therapeutics, Inc. | Frankenfield Christopher James | Officer | OPT+S | $0.64 | 7,030 | $4,522 | 24,766 |
| 2026-01-06 05:41 | 2026-01-05 | ARWR | Arrowhead Pharmaceuticals Inc. | Hamilton James C | Officer | SELL | $63.11 | 40,164 | $2,534,662 | 171,958 |
| 2026-01-06 04:02 | 2026-01-02 | IRON | Disc Medicine, Inc. | Khara Rahul | Officer | OPT+S | $78.69 | 6,500 | $511,472 | 37,793 |
| 2026-01-05 14:06 | 2025-12-31 | GLSI | Greenwich LifeSciences, Inc. | Patel Snehal | Director, Officer, 10% owner | BUY | $21.36 | 4,300 | $91,848 | 5,599,402 |
| 2026-01-05 16:00 | 2025-12-31 | HYPD | HYPERION DEFI, INC. | Knox David R. | Officer | BUY | $3.59 | 27,950 | $100,341 | 327,950 |
| 2026-01-06 02:01 | 2026-01-02 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | Officer | SELL | $7.43 | 16,667 | $123,776 | 1,308,103 |
| 2026-01-06 05:50 | 2026-01-05 | ARWR | Arrowhead Pharmaceuticals Inc. | O'Brien Patrick | Officer | SELL | $63.11 | 49,493 | $3,123,350 | 474,908 |
| 2026-01-06 04:31 | 2026-01-05 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | Officer | SELL | $32.98 | 57,661 | $1,901,406 | 409,190 |
| 2026-01-06 04:28 | 2026-01-05 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Director, Officer | SELL | $32.96 | 233,409 | $7,692,110 | 2,499,291 |
| 2026-01-06 04:22 | 2026-01-05 | ZYME | Zymeworks Inc. | Smith Jeffrey T L | Officer | OPT+S | $25.10 | 10,538 | $264,471 | 18,352 |
| 2026-01-05 15:00 | 2025-12-31 | RNXT | RenovoRx, Inc. | Agah Ramtin | Director, Officer | BUY | $0.86 | 9,795 | $8,424 | 788,460 |
| 2026-01-06 04:20 | 2026-01-05 | ZYME | Zymeworks Inc. | Galbraith Kenneth | Director, Officer | OPT+S | $25.10 | 54,343 | $1,363,841 | 193,266 |
| 2026-01-06 00:07 | 2026-01-02 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | Officer | SELL | $22.84 | 3,150 | $71,946 | 91,996 |
| 2026-01-06 05:39 | 2026-01-02 | ARWR | Arrowhead Pharmaceuticals Inc. | Anzalone Christopher Richard | Director, Officer | SELL | $66.10 | 13,187 | $871,703 | 3,792,739 |
| 2026-01-06 00:05 | 2026-01-05 | ALT | Altimmune, Inc. | Sohn Catherine A. | Director | BUY | $4.24 | 500 | $2,118 | 1,500 |
| 2026-01-06 04:31 | 2026-01-05 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | Officer | SELL | $32.90 | 57,661 | $1,896,972 | 189,891 |
| 2026-01-06 04:25 | 2026-01-02 | VKTX | Viking Therapeutics, Inc. | FOEHR MATTHEW W | Director | OPT+S | $35.11 | 16,000 | $561,694 | 132,036 |
| 2026-01-06 00:07 | 2025-12-31 | GALT | GALECTIN THERAPEUTICS INC | Jamil Khurram | Officer | OPT+S | $4.07 | 8,125 | $33,089 | 0 |
| 2026-01-06 00:59 | 2026-01-02 | UTHR | UNITED THERAPEUTICS Corp | CAUSEY CHRISTOPHER | Director | OPT+S | $500.01 | 1,000 | $500,015 | 4,190 |
| 2026-01-06 00:26 | 2026-01-05 | CYTK | CYTOKINETICS INC | Callos Andrew | Officer | OPT+S | $60.28 | 15,000 | $904,200 | 50,440 |
| 2026-01-06 00:15 | 2026-01-02 | RMTI | ROCKWELL MEDICAL, INC. | Hunter Heather | Officer | SELL | $0.84 | 2,868 | $2,396 | 132,523 |
| 2026-01-06 00:13 | 2026-01-02 | RMTI | ROCKWELL MEDICAL, INC. | Neri Jesse | Officer | SELL | $0.84 | 886 | $740 | 124,842 |
| 2026-01-03 04:25 | 2026-01-02 | ORKA | Oruka Therapeutics, Inc. | Sandler Laura Lee | Officer | OPT+S | $28.52 | 13,000 | $370,795 | 205,084 |
| 2026-01-03 00:20 | 2025-12-30 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $100.04 | 4,000 | $400,179 | 48,034 |
| 2026-01-03 01:25 | 2025-12-31 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $5.79 | 17,110 | $99,087 | 766,480 |
| 2026-01-03 05:00 | 2026-01-02 | JANX | Janux Therapeutics, Inc. | McIver Zachariah | Officer | SELL | $13.73 | 2,714 | $37,263 | 23,286 |
| 2026-01-03 05:00 | 2026-01-02 | JANX | Janux Therapeutics, Inc. | Dobek Maria | Officer | SELL | $13.73 | 1,462 | $20,073 | 15,373 |
| 2026-01-03 05:00 | 2026-01-02 | JANX | Janux Therapeutics, Inc. | DiRaimondo Thomas | Officer | SELL | $13.73 | 2,505 | $34,394 | 124,425 |
| 2026-01-03 05:00 | 2026-01-02 | JANX | Janux Therapeutics, Inc. | Winter Charles M. | Officer | SELL | $13.73 | 2,401 | $32,966 | 77,721 |
| 2026-01-03 05:00 | 2026-01-02 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Officer | SELL | $13.73 | 1,879 | $25,799 | 83,095 |
| 2026-01-03 05:00 | 2026-01-02 | JANX | Janux Therapeutics, Inc. | Campbell David Alan | Director, Officer | SELL | $13.73 | 8,072 | $110,829 | 284,982 |
| 2026-01-02 14:05 | 2025-12-30 | GLSI | Greenwich LifeSciences, Inc. | Patel Snehal | Director, Officer, 10% owner | BUY | $21.73 | 2,900 | $63,017 | 5,595,102 |
| 2026-01-03 02:12 | 2025-12-31 | ARQT | Arcutis Biotherapeutics Inc. | Burnett Patrick | Officer | SELL | $29.20 | 1,697 | $49,560 | 96,610 |
| 2026-01-03 00:15 | 2025-12-31 | ZLAB | Zai Lab Ltd | Amado Rafael | Officer | OPT+S | $17.43 | 10,787 | $188,039 | 52,391 |
| 2026-01-03 00:19 | 2025-12-31 | RCUS | Arcus Biosciences, Inc. | Goeltz II Robert C. | Officer | SELL | $23.38 | 6,552 | $153,186 | 67,924 |
| 2026-01-03 00:00 | 2025-12-30 | CUE | Cue Biopharma, Inc. | Sarraf Pasha | Director | BUY | $0.31 | 323,857 | $99,748 | 323,857 |
| 2026-01-03 01:25 | 2025-12-31 | VRDN | Viridian Therapeutics, Inc.\DE | Tousignant Jennifer | Officer | SELL | $31.16 | 2,272 | $70,796 | 0 |
| 2026-01-03 02:49 | 2026-01-02 | XENE | Xenon Pharmaceuticals Inc. | MORTIMER IAN | Director, Officer | OPT+S | $44.43 | 40,000 | $1,777,092 | 6,000 |
| 2026-01-03 01:00 | 2025-12-30 | RNXT | RenovoRx, Inc. | Agah Ramtin | Director, Officer | BUY | $0.83 | 205 | $169 | 778,665 |
| 2026-01-03 00:30 | 2025-12-30 | ANNX | Annexon, Inc. | Carson William H. | Director | BUY | $5.02 | 4,115 | $20,657 | 54,405 |
| 2026-01-03 00:39 | 2026-01-02 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer | SELL | $28.00 | 4,000 | $112,000 | 61,740 |
| 2026-01-03 04:18 | 2025-12-30 | AGIO | Agios Pharmaceuticals Inc. | Burns James William | Officer | OPT+S | $27.09 | 2,932 | $79,428 | 31,718 |
| 2026-01-03 04:16 | 2025-12-30 | AGIO | Agios Pharmaceuticals Inc. | Goff Brian | Director, Officer | OPT+S | $27.09 | 18,703 | $506,664 | 143,103 |
| 2026-01-03 04:15 | 2025-12-30 | AGIO | Agios Pharmaceuticals Inc. | Gheuens Sarah | Officer | OPT+S | $27.09 | 2,932 | $79,428 | 64,795 |
| 2026-01-03 04:15 | 2025-12-30 | AGIO | Agios Pharmaceuticals Inc. | Milanova Tsveta | Officer | OPT+S | $27.09 | 2,932 | $79,428 | 29,190 |
| 2026-01-03 04:14 | 2025-12-30 | AGIO | Agios Pharmaceuticals Inc. | Jones Cecilia | Officer | OPT+S | $27.09 | 2,932 | $79,428 | 37,394 |
| 2026-01-03 00:10 | 2025-12-31 | COCP | Cocrystal Pharma, Inc. | FROST PHILLIP MD ET AL | Director, 10% owner | BUY | $0.95 | 50,000 | $47,275 | 1,838,551 |
| 2026-01-03 00:04 | 2025-12-30 | FBRX | Forte Biosciences, Inc. | Riley Antony A | Officer | BUY | $26.33 | 9,680 | $254,833 | 41,520 |
| 2026-01-03 05:30 | 2025-12-30 | CRMD | CorMedix Inc. | DUNTON ALAN W | Director | OPT+S | $13.00 | 20,000 | $260,000 | 40,250 |
| 2026-01-03 00:05 | 2025-12-31 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | Director, Officer | BUY | $1.03 | 5,000 | $5,150 | 291,421 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.